J
Jim
Here is an artical about the CryoLife SG valves:
CryoLife receives 'CE Mark' approval for distribution of Model 700 synergraft tissue-engineered pulmonary heart valves in Europe
April 19, 2001
A Correspondent, Atlanta
CryoLife Inc, a life- science company involved in the development and commercialisation of tissue- engineered implantable heart valves, vascular and orthopaedic grafts and surgical adhesives, has received a "CE" (product certification) Mark allowing for the commercial distribution of its Model 700 SynerGraft tissue-engineered pulmonary heart valves within the European Community.
CryoLife's Model 700 SynerGraft pulmonary heart valve represents a major development in tissue-engineered replacement biologic devices for repair of damaged or diseased human tissues. The technology incorporates the use of a porcine pulmonary heart valve that has been depopulated of its porcine cells, leaving a collagen matrix that has the potential to repopulate with the recipient's own cells, providing a bioengineered human heart valve with structure and biodynamics similar to the recipient's own heart valve. It is anticipated that the tissue-engineered valve will have the capability to grow with the maturing of a child, thus potentially avoiding a series of heart valve replacement procedures.
Steven G. Anderson, President and Chief Executive Officer, CryoLife, Inc., said, "The addition of the Model 700 SynerGraft pulmonary heart valve demonstrates the potential for expansion of the SynerGraft technology platform. CryoLife now provides two tissue-engineered heart valves for patients requiring heart valve replacement, the SynerGraft Model 500 aortic valve and the Model 700 pulmonary valve, thus making CryoLife a technology leader in tissue-engineered products. In advanced animal studies, both of these valves have been repopulated with the recipient's own cells."
The CE Mark for the SynerGraft Model 700 tissue-engineered pulmonary heart valve, granted by Lloyd's Register Quality Assurance Limited (LRQA) of Coventry, England, represents the sixth CE Mark designation awarded for CryoLife products. CryoLife was awarded its CE Mark for the SynerGraft Model 500 heart valve last year. CryoLife was awarded CE Marks for its stentless porcine aortic and pulmonary heart valves in 1996 and 1998, respectively. CryoLife was also awarded CE Marks in 1998 and 1999 for its BioGlue surgical adhesive for applications in both vascular and pulmonary repairs.
Domestically, CryoLife scientists and regulatory personnel are working on the development of additional SynerGraft Model 500 and 700 clinical data relating to an IDE (Investigational Device Exemption) application to the U.S. Food and Drug Administration to use SynerGraft Model 500 and 700 pulmonary heart valves in human clinical trials. These IDE applications are expected to be made in the fourth quarter of 2001.
CryoLife receives 'CE Mark' approval for distribution of Model 700 synergraft tissue-engineered pulmonary heart valves in Europe
April 19, 2001
A Correspondent, Atlanta
CryoLife Inc, a life- science company involved in the development and commercialisation of tissue- engineered implantable heart valves, vascular and orthopaedic grafts and surgical adhesives, has received a "CE" (product certification) Mark allowing for the commercial distribution of its Model 700 SynerGraft tissue-engineered pulmonary heart valves within the European Community.
CryoLife's Model 700 SynerGraft pulmonary heart valve represents a major development in tissue-engineered replacement biologic devices for repair of damaged or diseased human tissues. The technology incorporates the use of a porcine pulmonary heart valve that has been depopulated of its porcine cells, leaving a collagen matrix that has the potential to repopulate with the recipient's own cells, providing a bioengineered human heart valve with structure and biodynamics similar to the recipient's own heart valve. It is anticipated that the tissue-engineered valve will have the capability to grow with the maturing of a child, thus potentially avoiding a series of heart valve replacement procedures.
Steven G. Anderson, President and Chief Executive Officer, CryoLife, Inc., said, "The addition of the Model 700 SynerGraft pulmonary heart valve demonstrates the potential for expansion of the SynerGraft technology platform. CryoLife now provides two tissue-engineered heart valves for patients requiring heart valve replacement, the SynerGraft Model 500 aortic valve and the Model 700 pulmonary valve, thus making CryoLife a technology leader in tissue-engineered products. In advanced animal studies, both of these valves have been repopulated with the recipient's own cells."
The CE Mark for the SynerGraft Model 700 tissue-engineered pulmonary heart valve, granted by Lloyd's Register Quality Assurance Limited (LRQA) of Coventry, England, represents the sixth CE Mark designation awarded for CryoLife products. CryoLife was awarded its CE Mark for the SynerGraft Model 500 heart valve last year. CryoLife was awarded CE Marks for its stentless porcine aortic and pulmonary heart valves in 1996 and 1998, respectively. CryoLife was also awarded CE Marks in 1998 and 1999 for its BioGlue surgical adhesive for applications in both vascular and pulmonary repairs.
Domestically, CryoLife scientists and regulatory personnel are working on the development of additional SynerGraft Model 500 and 700 clinical data relating to an IDE (Investigational Device Exemption) application to the U.S. Food and Drug Administration to use SynerGraft Model 500 and 700 pulmonary heart valves in human clinical trials. These IDE applications are expected to be made in the fourth quarter of 2001.